Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 167

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Cyclic GMP and protein kinase‐G in myocardial ischaemia‐reperfusion: opportunities and obstacles for survival signaling

Open access
Burley, D S, Ferdinandy, P, Baxter, G F·2007·British Journal of Pharmacology

Abstract

It is clear that multiple signalling pathways regulate the critical balance between cell death and survival in myocardial ischaemia–reperfusion. Recent attention has focused on the activation of survival or salvage kinases, particularly during reperfusion, as a common mechanism of many cardioprotective interventions. The phosphatidyl inositol 3′‐hydroxy kinase/Akt complex (PI3K/Akt) and p42/p44 mitogen‐activated protein kinase cascades have been widely promoted in this respect but the cyclic guanosine 3′,5′‐monophosphate/cGMP‐dependent protein kinase (cGMP/PKG) signal transduction cassette has been less systematically investigated as a survival cascade. We propose that activation of the cGMP/PKG signalling pathway, following activation of soluble or particulate guanylate cyclases, may play a pivotal role in survival signalling in ischaemia–reperfusion, especially in the classical preconditioning, delayed preconditioning and postconditioning paradigms. The resurgence of interest in reperfusion injury, largely as a result of postconditioning‐related research, has confirmed that the cGMP/PKG pathway is a pivotal salvage mechanism in reperfusion. Numerous studies suggest that the infarct‐limiting effects of preconditioning and postconditioning, exogenously donated nitric oxide (NO), natriuretic peptides, phosphodiesterase inhibitors, and other diverse drugs and mediators such as HMG co‐A reductase inhibitors (statins), Rho‐kinase inhibitors and adrenomedullin, whether given before and during ischaemia, or specifically at the onset of reperfusion, may be mediated by activation or enhancement of the cGMP pathway, either directly or indirectly via endogenous NO generation downstream of PI3K/Akt. Putative mechanisms of protection include PKG regulation of Ca 2+homeostasis through the modification of sarcoplasmic reticulum Ca 2+uptake mechanisms, and PKG‐induced opening of ATP‐sensitive K+channels during ischaemia and/or reperfusion. At present, significant technical obstacles in defining the precise roles played by cGMP/PKG signalling include the heavy reliance on pharmacological PKG inhibitors of uncertain selectivity, difficulties in determining PKG activity in intact tissue, and the growing recognition that intracellular compartmentalisation of the cGMP pool may contribute markedly to the nucleotide's biological actions and biochemical determination. Overall, the body of experimental evidence suggests that cGMP/PKG survival signalling ameliorates irreversible injury associated with ischaemia–reperfusion and may be a tractable therapeutic target. British Journal of Pharmacology(2007)152, 855–869; doi:10.1038/sj.bjp.0707409; published online 13 August 2007

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjp.0707409

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 167

Metadata

Authors
Burley, D. S., Ferdinandy, P., & Baxter, G. F.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2007-11
Volume
152
Issue
6
Pages
855-869
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W2081444493
Cited by
167
References
6
FWCI
10.98
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cyclic GMP and protein kinase‐G in myocardial ischaemia‐reperfusion: opportunities and obstacles for survival signaling. https://app.cochat.ai/papers/10.1038/sj.bjp.0707409
The paper
Burley, D. S., Ferdinandy, P., & Baxter, G. F. (2007). Cyclic GMP and protein kinase‐G in myocardial ischaemia‐reperfusion: opportunities and obstacles for survival signaling. British Journal of Pharmacology. https://doi.org/10.1038/sj.bjp.0707409

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.